Cargando…

Raynaud’s Phenomenon with Focus on Systemic Sclerosis

Raynaud’s phenomenon is a painful vascular condition in which abnormal vasoconstriction of the digital arteries causes blanching of the skin. The treatment approach can vary depending on the underlying cause of disease. Raynaud’s phenomenon can present as a primary symptom, in which there is no evid...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maciejewska, Magdalena, Sikora, Mariusz, Maciejewski, Cezary, Alda-Malicka, Rosanna, Czuwara, Joanna, Rudnicka, Lidia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9105786/ https://www.ncbi.nlm.nih.gov/pubmed/35566614 http://dx.doi.org/10.3390/jcm11092490

Ejemplares similares

Future Treatment Options in Systemic Sclerosis—Potential Targets and Ongoing Clinical Trials
por: Bohdziewicz, Anna, et al.
Publicado: (2022)

Copeptin as a Biomarker of Microcirculation Alterations in Systemic Sclerosis
por: Maciejewska, Magdalena, et al.
Publicado: (2023)

Hypoxia-Inducible Factor-1α (HIF-1α) as a Biomarker for Changes in Microcirculation in Individuals with Systemic Sclerosis
por: Maciejewska, Magdalena, et al.
Publicado: (2023)

Audiovestibular Manifestations in Patients with Primary Raynaud’s Phenomenon and Raynaud’s Phenomenon Secondary to Systemic Sclerosis
por: Amor-Dorado, Juan Carlos, et al.
Publicado: (2023)

The Clinical Significance of Salusins in Systemic Sclerosis—A Cross-Sectional Study
por: Nowaczyk, Joanna, et al.
Publicado: (2023)

Hyperspectral imaging in systemic sclerosis-associated Raynaud phenomenon
por: Teaw, Shannon, et al.
Publicado: (2023)

Raynaud’s phenomenon
por: Solomons, HD
Publicado: (2011)

Raynaud's Phenomenon
por: Shah, Jehan, et al.
Publicado: (2013)

The Gut Microbial Metabolite Trimethylamine N-Oxide is Linked to Specific Complications of Systemic Sclerosis
por: Stec, Albert, et al.
Publicado: (2023)

Advances in the treatment of Raynaud’s phenomenon
por: Levien, Terri L
Publicado: (2010)

Endothelin Receptor Antagonists for the Treatment of Raynaud's Phenomenon and Digital Ulcers in Systemic Sclerosis
por: Arefiev, Kait, et al.
Publicado: (2011)

Reduced levels of S-nitrosothiols in plasma of patients with systemic sclerosis and Raynaud's phenomenon
por: Kundu, Devi, et al.
Publicado: (2014)

Altered serum level of metabolic and endothelial factors in patients with systemic sclerosis
por: Stochmal, Anna, et al.
Publicado: (2019)

Systemic lupus erythematosus and Raynaud's phenomenon
por: Heimovski, Flavia Emilie, et al.
Publicado: (2015)

Recent achievements in the management of Raynaud’s phenomenon
por: Baumhäkel, Magnus, et al.
Publicado: (2010)

The Clinical Significance of Serum Biomarkers of the Intestinal Barrier in Systemic Sclerosis: A Cross-Sectional Study
por: Stec, Albert, et al.
Publicado: (2023)

Rheopheresis for Digital Ulcers and Raynaud's Phenomenon in Systemic Sclerosis Refractory to Conventional Treatments
por: Korsten, Peter, et al.
Publicado: (2019)

Botulinum toxin in the treatment of Raynaud phenomenon in patients with systemic sclerosis: a systemic review
por: Cai, Ruyi, et al.
Publicado: (2022)

Raynaud's phenomenon in pediatric age
por: Tavares, M, et al.
Publicado: (2011)

Raynaud's Phenomenon: Beware of Cancers!
por: Aqodad, Zahida, et al.
Publicado: (2021)

Solvent-Induced Raynaud’s Phenomenon
por: Rodrigues, Helena, et al.
Publicado: (2023)

Circulating peroxisome proliferator-activated receptor γ is elevated in systemic sclerosis
por: Żółkiewicz, Jakub, et al.
Publicado: (2019)

Association between systemic sclerosis, palmar fasciitis with polyarthritis, Raynaud’s phenomenon and erythromelalgia with underlying malignancy
por: Nowak, Katarzyna, et al.
Publicado: (2022)

Application of the 2013 ACR/EULAR classification criteria for systemic sclerosis to patients with Raynaud’s phenomenon
por: Park, Jin-Su, et al.
Publicado: (2015)

Self-Reported Systemic Sclerosis-Related Symptoms Are More Prevalent in Subjects with Raynaud’s Phenomenon in the Lifelines Population: Focus on Pulmonary Complications
por: van de Zande, Saskia Corine, et al.
Publicado: (2023)

Prevalence of Raynaud’s Phenomenon in Saudi Arabia
por: Mustafa, Mohammad, et al.
Publicado: (2022)

Lower limb ulcer and Raynaud's phenomenon
por: Chérif, Mohammad Yassine, et al.
Publicado: (2022)

Glomus Tumor Presenting as Raynaud's Phenomenon
por: Abdelrahman, M. H., et al.
Publicado: (2012)

Monostotic fibrous dysplasia with Raynaud's phenomenon
por: Kumar, K. V. S. Hari, et al.
Publicado: (2015)

Pacinian hyperplasia presenting with Raynaud’s phenomenon
por: Pickrell, Brent B., et al.
Publicado: (2019)

Raynaud’s Phenomenon: A Brush Up!
por: Swarnkar, Bhavya, et al.
Publicado: (2023)

A violist with asymmetrical Raynaud’s phenomenon
por: Silva, Beatriz C, et al.
Publicado: (2023)

Raynaud’s phenomenon in childhood-onset systemic lupus erythematous
por: Jiang, Qi, et al.
Publicado: (2022)

Artifactual Hypoglycaemia in Systemic Sclerosis and Raynaud's Phenomenon: A Clinical Case Report and Short Review
por: Bishay, RH, et al.
Publicado: (2016)

Botulinum toxin A in the treatment of Raynaud's phenomenon: a systematic review
por: Żebryk, Paweł, et al.
Publicado: (2015)

Immunopathogenesis of Atopic Dermatitis: Focus on Interleukins as Disease Drivers and Therapeutic Targets for Novel Treatments
por: Makowska, Karolina, et al.
Publicado: (2023)

The inhibitory effects of camptothecin, a topoisomerase I inhibitor, on collagen synthesis in fibroblasts from patients with systemic sclerosis
por: Czuwara-Ladykowska, Joanna, et al.
Publicado: (2001)

Raynaud’s Phenomenon: Reviewing the Pathophysiology and Management Strategies
por: Nawaz, Iqra, et al.
Publicado: (2022)

Digital Thermography of the Fingers and Toes in Raynaud's Phenomenon
por: Lim, Mie Jin, et al.
Publicado: (2014)

Risperidone Related Raynaud’s Phenomenon: An Adolescent Case
por: Güneş, Serkan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_j65puicvp8495af4bctjcnh46f